Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

The published long-term data suggests that the treatment could maintain its dominant position in the CF market.

At ARVO 2025, in Salt Lake City, Utah, Viha Vig, talked about her poster presentation investigating the relationship between ocular and systemic mitochondrial diseases and dementia ...

Avalyn’s Phase 1a trial of AP02 assessed clinical tolerability and pharmacokinetic profiles in three SAD cohorts, up to a maximum 2.0 mg dose in HVs; two BAL cohorts in HVs; and one cohort of patients ...

Finance Income, net was $1.0 million for the three months ended March 31, 2025, compared to $0.7 million in the same period ...

Xenon MRIDURHAM, NC and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

DUBAI, 17th May, 2025 (WAM) - The fifth edition of the Interdisciplinary Urology Care Consortium - IUCC 2025 officially opened today in Dubai, bringing together over 80 speakers, 30+ participating ...

Title: ZW1528, a Bispecific Antibody Targeting IL-4Ra and IL-33, Potently Inhibits Key Mediators of Airway Inflammation ...

GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion ...